Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2011

01-09-2011 | Short Communication

High doses of oxycodone–naloxone combination may provide poor analgesia

Authors: Sebastiano Mercadante, Patrizia Ferrera, Claudio Adile

Published in: Supportive Care in Cancer | Issue 9/2011

Login to get access

Abstract

Several studies have shown that an oxycodone/naloxone combination (ratio 2:1) provides analgesia and less constipation in non-cancer patients receiving relatively low doses of this formulation. A case report of a cancer patient who was receiving increasing doses of oxycodone with an unexpected declining analgesia is presented. The substitution with the same doses (240 mg/day) of regular controlled-release oxycodone was effective in regaining adequate analgesia.
Literature
1.
Bercovitch M, Adunsky A (2006) High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20:33–39PubMed
2.
Hanks GW, and Expert Working group of the Research Network of the European Association for Palliative Care (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593PubMedCrossRef
3.
Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649–671PubMedCrossRef
4.
Leppert W (2010) Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep 62:578–591PubMed
5.
Lowenstein O, Leyendecker P, Lux E, Blagden M et al (2010) Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomized, double-blind clinical trials. BMC Clin Pharmacol 10:12PubMedCrossRef
6.
Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K (2000) Oral naloxone reverses opioid-associated constipation. Pain 84:105–109PubMedCrossRef
7.
Meissner W, Leyendecker P, Meuller_lissner S, Nadstawek J, Hopp M, Ruckes C (2009) A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-indued constipation. Eur J Pain 13:56–64PubMedCrossRef
8.
Mercadante S, Ferrera P, David F, Casuccio A (2011) The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care 28:242–244PubMedCrossRef
9.
Mueller-Lissner S (2010) Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther 27:581–590PubMedCrossRef
10.
Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW (2006) Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 166:837–843PubMedCrossRef
11.
Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejco J et al (2010) Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 64:763–774PubMedCrossRef
12.
Simpson K, Keyndecker P, Hopp M, Muller-Lissner S, Lowenstein O et al (2008) Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe non cancer pain. Curr Med Res Opin 24:3503–3512PubMedCrossRef
13.
Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P et al (2008) Single and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in a opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 30:2051–2067PubMedCrossRef
Metadata
Title
High doses of oxycodone–naloxone combination may provide poor analgesia
Authors
Sebastiano Mercadante
Patrizia Ferrera
Claudio Adile
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1205-x

Other articles of this Issue 9/2011

Supportive Care in Cancer 9/2011 Go to the issue

Short Communication

What kind of cancer information do Internet users need?

Original Article

Psychosocial needs of ethnic minority, inner-city, pediatric cancer patients

Short Communication

Oral rehabilitation with implant-based prostheses of two adult patients treated for childhood rhabdomyosarcoma

Original Article

Quality of life concerns and depression among hematopoietic stem cell transplant survivors

Original Article

Use of unnecessary medications by patients with advanced cancer: cross-sectional survey

Original Article

Characterization of cancer-induced bone pain: an exploratory study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits